{"filings":[{"id":470721,"accession_number":"0001104659-26-062509","cik":1628808,"company_name":"Profound Medical Corp.","ticker":"PROF","form_type":"8-K","filed_at":"2026-05-15T20:06:16+00:00","items":["5.07","9.01"],"status":"ready","headline":"Profound Medical 2026 AGM: All director nominees elected; incentive plan approved with 36% against","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Arthur Rosenthal re-elected with 79.0% for vs 21.0% withheld; lowest support among eight nominees.","Unallocated RSUs/DSUs under LTIP approved: 63.9% for, 36.1% against.","PricewaterhouseCoopers LLP reappointed as auditor with 99.5% for.","Total shares outstanding 36,337,637 as of April 2, 2026 record date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.15,"market_cap_usd":345207533.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":444796,"accession_number":"0001171843-26-003441","cik":1628808,"company_name":"Profound Medical Corp.","ticker":"PROF","form_type":"8-K","filed_at":"2026-05-14T21:06:16+00:00","items":["7.01","9.01"],"status":"ready","headline":"Profound Medical to present TULSA Procedure data at AUA2026 and explore PSMA PET integration","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Four oral presentations on TULSA Procedure at AUA Annual Meeting in Washington, DC on May 16, 2026.","Presenters include Mayo Clinic's Dr. Pathak, Dr. Anttinen (Finland), and Dr. Miura (Japan) covering registry, phase 2 trial, and real-world data.","Launches initiative to explore integration of PSMA PET molecular imaging with TULSA-PRO software for treatment planning and monitoring.","Hosts demonstrations of TULSA-PRO and Siemens MAGNETOM Free.Max MR at booth #413 at AUA2026.","Note: 0.55T MRI compatibility (Free.Max) not yet commercially available in all markets, including the U.S."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":345207533.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94201,"accession_number":"0001171843-26-003160","cik":1628808,"company_name":"Profound Medical Corp.","ticker":"PROF","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Profound Medical Reports Strong Q1 2026 Results with 104% Revenue Growth and Humana Coverage","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue grew 104% year-over-year to $5.3M, with $2.5M recurring and $2.9M capital equipment.","Net loss improved 34% to $7.0M ($0.19 per share) from $10.7M in Q1 2025.","Humana became first national U.S. payor to cover the TULSA Procedure, adding ~8.5M covered lives.","CAPTAIN trial met primary safety endpoint; TULSA INDEX20 average procedures per quarter rose to 11.3.","Full-year 2026 revenue guidance set at ~$25M, representing 56% growth over prior year."],"consensus_eps_estimate":null,"consensus_eps_actual":0.19,"consensus_revenue_estimate":null,"consensus_revenue_actual":5337000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":345207533.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94200,"accession_number":"0001171843-26-002497","cik":1628808,"company_name":"Profound Medical Corp.","ticker":"PROF","form_type":"8-K","filed_at":"2026-04-16T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Profound Medical to release Q1 2026 results on May 7, conference call to follow","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Plans to release Q1 2026 financial results after market close on May 7, 2026.","Conference call to discuss results and business developments at 4:30 p.m. ET on same day.","Dial-in: 1-800-717-1738 (North America) or 1-646-307-1865 (International).","No preliminary financial results disclosed in this announcement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":345207533.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94199,"accession_number":"0001171843-26-002426","cik":1628808,"company_name":"Profound Medical Corp.","ticker":"PROF","form_type":"8-K","filed_at":"2026-04-14T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Profound Medical to present at Bloom Burton healthcare conf on Apr 22, 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Presentation at 2026 Bloom Burton & Co. Healthcare Investor Conference on Apr 22, 2026, 10:00 a.m. ET.","Live broadcast and archive available on company IR page at profoundmedical.com.","No financial results or material business updates were disclosed in the filing.","Routine conference participation announcement; no guidance or new data provided."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":345207533.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94198,"accession_number":"0001171843-26-002146","cik":1628808,"company_name":"Profound Medical Corp.","ticker":"PROF","form_type":"8-K","filed_at":"2026-04-01T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Profound Medical to present TULSA-PRO data at SIR 2026 in Toronto, April 11-15","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Five oral presentations on April 12 during 'Men's Health 1' session at SIR Annual Meeting.","Categorical course 'Prostate Interventions: TULSA and Beyond' on April 13 featuring TULSA.","Presentations include CAPTAIN trial data comparing TULSA vs robotic prostatectomy for intermediate-risk prostate cancer.","Other topics: TULSA for recurrent prostate cancer, extreme apex cancer, and automated segmentation validation.","CEO says growing acceptance of TULSA as mainstream treatment for prostate disease."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":345207533.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106400,"accession_number":"0001171843-26-001971","cik":1628808,"company_name":"Profound Medical Corp.","ticker":"PROF","form_type":"8-K","filed_at":"2026-03-27T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Texas Prostate hits 100th TULSA Procedure; volumes up 500% under new Medicare model","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Texas Prostate, led by Dr. James Cochran, performed its 100th TULSA Procedure at Dallas Medical Center.","Procedure volumes increased 500% after transitioning from private pay to a Medicare model via Dallas Medical Center.","Dr. Cochran cited TULSA's MRI-guidance and thermography for broader treatment range and improved safety versus HIFU.","CEO Arun Menawat said the model demonstrates a path for accelerating TULSA adoption across prostate care."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":345207533.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106399,"accession_number":"0001171843-26-001553","cik":1628808,"company_name":"Profound Medical Corp.","ticker":"PROF","form_type":"8-K","filed_at":"2026-03-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"CAPTAIN trial meets primary safety endpoint: TULSA superior to robotic RP on function preservation","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Primary composite endpoint met: 50% of TULSA patients preserved erectile function and continence at 6 months vs 24% for RP (p<0.05, risk ratio 2.1).","TULSA preserved pad-free continence in 84% and erectile function in 56% of men at 6 months; RP: 49% and 47% respectively.","Perioperative benefits: zero blood loss (0 mL vs 150 mL), median 0.3-day hospital stay vs 1.1 days, no ICU admissions versus 1.6% for RP.","Serious complications requiring hospitalization within 90 days: 0.7% for TULSA vs 6.3% for RP (p<0.05).","Secondary oncologic endpoints for TULSA arm (12-month biopsy and MRI) expected later in 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":345207533.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106398,"accession_number":"0001104659-26-025822","cik":1628808,"company_name":"Profound Medical Corp.","ticker":"PROF","form_type":"8-K","filed_at":"2026-03-10T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Kris Shah resigns; Frank Baylis appointed to board of Profound Medical","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Kris Shah resigned from Profound Medical's board effective March 5, 2026; no disagreement cited.","Frank Baylis appointed to fill vacancy; will serve until 2026 annual meeting.","Baylis receives standard non-employee director compensation: $50k annual retainer (pro-rated) plus equity awards.","Baylis also entered into company's standard indemnification agreement.","No arrangements or understandings with others; no family relationships with directors/officers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":345207533.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106397,"accession_number":"0001171843-26-001406","cik":1628808,"company_name":"Profound Medical Corp.","ticker":"PROF","form_type":"8-K","filed_at":"2026-03-09T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Profound Medical to present first CAPTAIN trial outcomes at EAU 2026, host investor call March 13","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First CAPTAIN trial outcomes (TULSA vs radical prostatectomy) presented at EAU 2026 on March 13 at 9:40 a.m. EDT.","Investor webinar at 11:30 a.m. EDT on March 13 with Dr. Laurence Klotz reviewing data and commercial implications.","Management to participate in Roth Conference March 22-24 in Dana Point, CA; one-on-one meetings."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":345207533.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106396,"accession_number":"0001171843-26-001362","cik":1628808,"company_name":"Profound Medical Corp.","ticker":"PROF","form_type":"8-K","filed_at":"2026-03-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Profound Medical Q4 revenue $6M (+43% YoY), net loss $8.2M; installed base 78 TULSA-PRO","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue record $6.0M (+43% YoY); net loss $8.2M ($0.27/sh) vs $4.9M loss year ago.","FY2025 revenue $16.1M (up from $10.7M); net loss $42.6M ($1.41/sh) vs $27.8M loss.","TULSA-PRO installed base 78, pipeline 110; expects ~120 installs by end of 2026.","Dec 2025 financing: $36M US offering + $6.45M Canadian private placement; cash $59.7M.","Board change: Kris Shah resigns, Frank Baylis appointed; Baylis co-founded Baylis Medical (sold for $1.75B)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":345207533.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106395,"accession_number":"0001171843-26-000791","cik":1628808,"company_name":"Profound Medical Corp.","ticker":"PROF","form_type":"8-K","filed_at":"2026-02-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Profound Medical schedules Q4/FY2025 earnings release and call for March 5, 2026","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Earnings results will be released after market close on Thursday, March 5, 2026.","Conference call to follow at 4:30 p.m. ET on the same day.","Call registration link and webcast available via company's Investors page.","No preliminary financial results or guidance provided in this announcement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":345207533.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106394,"accession_number":"0001171843-26-000772","cik":1628808,"company_name":"Profound Medical Corp.","ticker":"PROF","form_type":"8-K","filed_at":"2026-02-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Profound Medical receives Mount Logan Award; touts 4,000th TULSA case, new US codes, direct sales expansion","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["INOVAIT honored Profound with the 2025-2026 Mount Logan Award for TULSA Procedure commercialization.","Company treated 4,000th TULSA patient and secured new Medicare reimbursement codes in the US.","Regained exclusive Canadian distribution rights; deploying direct sales team in North America.","Sunnybrook Health Sciences Centre performed over 100 TULSA procedures despite no provincial insurance coverage."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":345207533.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106393,"accession_number":"0001171843-26-000643","cik":1628808,"company_name":"Profound Medical Corp.","ticker":"PROF","form_type":"8-K","filed_at":"2026-02-05T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Profound Medical announces PRO FAMILIA hospital completes 500th Sonalleve procedure","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["PRO FAMILIA Specialist Hospital in Rzeszów, Poland performed its 500th Sonalleve MRI-guided focused ultrasound procedure.","Sonalleve provides non-surgical treatment for uterine fibroids and adenomyosis, with no incisions, no blood loss, and no overnight stay.","Over 4,000 women treated globally with 10 Sonalleve devices in Europe, China, and Southeast Asia.","CEO Arun Menawat notes Sonalleve international growth while U.S. focus remains on TULSA-PRO commercialization.","Approximately $10 million in research grants from European and Canadian organizations over five years for Sonalleve studies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":345207533.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106392,"accession_number":"0001171843-26-000450","cik":1628808,"company_name":"Profound Medical Corp.","ticker":"PROF","form_type":"8-K","filed_at":"2026-01-28T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Profound Medical announces two February investor conferences","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Lake Street Life-Sciences Invitational Feb 4-5 in Scottsdale, AZ; one-on-one meetings.","BTIG 13th Annual MedTech Conference Feb 10-11 in Snowbird, UT; one-on-one meetings.","No webcasts will be available due to the format of the events."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":345207533.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106391,"accession_number":"0001171843-26-000273","cik":1628808,"company_name":"Profound Medical Corp.","ticker":"PROF","form_type":"8-K","filed_at":"2026-01-15T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Mount Sinai treats first prostate cancer patient with Profound's TULSA-PRO system","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Mount Sinai Hospital (ranked #6 for Urology) is first in Metro New York to offer TULSA-PRO incision-free, MRI-guided prostate treatment.","Procedure uses AI-powered, directional ultrasound from inside urethra to heat tissue to 55-57°C while protecting nerves; no blood loss or overnight stay.","Patient discharged same day; initial treatment outcome positive.","Profound CEO Arun Menawat noted collaboration between Urology and Interventional Radiology at Mount Sinai."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":345207533.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106390,"accession_number":"0001171843-26-000210","cik":1628808,"company_name":"Profound Medical Corp.","ticker":"PROF","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Profound Medical TULSA-PRO installed base reaches 78 systems, exceeding 2025 target of 75","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["TULSA-PRO installed base stood at 78 systems as of Dec. 31, 2025, above the goal of 75.","Qualified sales pipeline grew to 97 new systems in Verify, Negotiate, or Contracting stages.","CEO expects higher patient treatment rates and recurring revenue as installed base expands.","Q4 and full-year 2025 financial results to be released near end of February 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":345207533.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106389,"accession_number":"0001171843-26-000096","cik":1628808,"company_name":"Profound Medical Corp.","ticker":"PROF","form_type":"8-K","filed_at":"2026-01-06T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Johns Hopkins Hospital treats first commercial TULSA-PRO case, expanding access to advanced prostate care","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Johns Hopkins Hospital treated its first non-clinical-trial prostate cancer patient using Profound's TULSA-PRO system.","Milestone coincides with the opening of Johns Hopkins Medicine's new interventional MRI suite.","TULSA-PRO delivers robotically controlled directional ultrasound under real-time MRI thermography to ablate prostate tissue.","Johns Hopkins was an early participant in the TACT and CAPTAIN trials that supported FDA clearance of TULSA-PRO."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":345207533.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122748,"accession_number":"0001104659-25-125344","cik":1628808,"company_name":"Profound Medical Corp.","ticker":"PROF","form_type":"8-K","filed_at":"2025-12-31T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"Profound Medical closes $6.45M private placement of 921,428 shares at $7.00 each","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 921,428 common shares at US$7.00 per share to Canadian investors for gross proceeds of ~US$6.45M.","Proceeds to be used for sales and marketing expansion, working capital, R&D, strategic transactions, and general corporate purposes.","Shares subject to four-month-plus-one-day hold period under Canadian securities laws.","Company to file resale registration statement with SEC within four months of closing.","Offering closed on December 30, 2025, under Regulation S exemption from U.S. registration."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":345207533.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122747,"accession_number":"0001104659-25-123211","cik":1628808,"company_name":"Profound Medical Corp.","ticker":"PROF","form_type":"8-K","filed_at":"2025-12-19T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Profound Medical prices $36M registered direct offering and up to $4M private placement at $7.00/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 5,142,870 common shares at $7.00 each in registered direct offering; gross proceeds ~$36M.","Planned private placement in Canada of up to 571,428 common shares at $7.00 for up to $4M additional proceeds.","Both tranches have no warrant coverage; placement agent is Konik Capital Partners (5% cash fee).","Registered direct closing expected Dec 22, 2025; private placement closing on or before Dec 30, 2025.","Net proceeds for sales/marketing expansion, working capital, R&D, and strategic transactions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":345207533.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122746,"accession_number":"0001171843-25-007654","cik":1628808,"company_name":"Profound Medical Corp.","ticker":"PROF","form_type":"8-K","filed_at":"2025-11-28T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Profound Medical launches AI-powered TULSA-AI Volume Reduction module for BPH; TAM could triple to ~600K patients","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Launched TULSA-AI Volume Reduction module for BPH at RSNA; reduces procedure times and enables same-day stacking.","CEO Arun Menawat says module could triple total addressable market to ~600,000 patients annually.","CAPTAIN randomized trial data shows TULSA superior to robotic prostatectomy in blood loss, length of stay, and pain.","TULSA Procedure is the only incision-free therapy for both prostate cancer and BPH with customizable precision.","Profound to present new TULSA-PRO data at RSNA and SUO meetings through Dec 5, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":345207533.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122745,"accession_number":"0001171843-25-007224","cik":1628808,"company_name":"Profound Medical Corp.","ticker":"PROF","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Profound Medical signs exclusive distribution deal for TULSA-PRO in Australia, New Zealand","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Exclusive distribution & supply agreement with Getz Healthcare for TULSA-PRO system in Australia and New Zealand.","TULSA-PRO is an AI-powered, MRI-guided robotic system for real-time prostate ablation without surgery or radiation.","Partnership leverages Getz Healthcare's established distribution network in the region.","Profound also deploys direct sales in North America while partnering with strategic distributors internationally."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":345207533.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122744,"accession_number":"0001171843-25-007221","cik":1628808,"company_name":"Profound Medical Corp.","ticker":"PROF","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Profound Medical signs exclusive Saudi distribution deal for TULSA-PRO and Sonalleve with Al Faisaliah Medical Systems","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Exclusive distribution and supply agreement for TULSA-PRO and Sonalleve in Saudi Arabia with Al Faisaliah Medical Systems Co.","All regulatory approvals to import and sell the technologies in Saudi Arabia are already in place.","Saudi Arabia is the largest healthcare market in the Middle East; deal expands Profound's presence.","CEO Arun Menawat says FMS has a proven track record in introducing advanced medical technologies in the Kingdom."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":345207533.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122743,"accession_number":"0001171843-25-007188","cik":1628808,"company_name":"Profound Medical Corp.","ticker":"PROF","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Profound Medical regains exclusive Canadian distribution rights for TULSA-PRO from Knight Therapeutics","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["One-time cash payment of CDN$90,000 (US$64,000) and 5% royalty on Canadian net sales for 15 years.","Only one Canadian site (Sunnybrook Health Sciences Centre) currently offers the TULSA Procedure; >100 procedures performed there.","Plans to use CAPTAIN trial results (comparing TULSA vs robotic prostatectomy) for provincial insurance coverage applications starting 2026.","Regained rights allow Profound to deploy its own direct North American sales team; interim concierge service model for new Canadian sites.","Knight's CEO notes strategic fit: Knight focuses on pharma, while Profound is better suited to commercialize this complex medical device."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":345207533.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122742,"accession_number":"0001171843-25-006317","cik":1628808,"company_name":"Profound Medical Corp.","ticker":"PROF","form_type":"8-K","filed_at":"2025-10-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Profound Medical reports preliminary Q3 revenue $5.2-5.3M, up 84-87% YoY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary unaudited Q3 2025 revenue of $5.2-5.3M vs $2.8M in Q3 2024, growth 84-87%.","Gross margin expected ~72% compared to 64% in prior-year period.","TULSA-PRO installed base grew to 67 from 60; full-year target of at least 75 systems.","Full Q3 2025 results and conference call scheduled for November 13, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":1.14,"consensus_revenue_estimate":null,"consensus_revenue_actual":10121000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":345207533.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139430,"accession_number":"0001171843-25-005427","cik":1628808,"company_name":"Profound Medical Corp.","ticker":"PROF","form_type":"8-K","filed_at":"2025-08-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Profound Medical reports Q2 net loss of $15.7M; revenue flat at $2.2M; maintains 70-75% FY growth guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $15.7M ($0.52/share) vs $6.9M ($0.28/share) in Q2 2024; revenue unchanged at $2.2M.","Gross margin improved to 73% from 64% on manufacturing efficiencies; operating expenses rose to $15.4M from $9.3M.","Same-store TULSA-PRO procedure volumes up 10% sequentially; pipeline of 80 new systems in qualifying stages.","CEO cites short-term capital sales delays but reaffirms FY 2025 revenue growth target of 70-75% YoY.","Cash position $35.2M; first commercial BPH treatment with TULSA-AI Volume Reduction Module conducted; full launch expected Q4 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":0.88,"consensus_revenue_estimate":null,"consensus_revenue_actual":4832000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":345207533.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157014,"accession_number":"0001171843-25-003672","cik":1628808,"company_name":"Profound Medical Corp.","ticker":"PROF","form_type":"8-K","filed_at":"2025-06-04T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Profound Medical names former NFL safety Leonard Wheeler as TULSA-PRO Global Ambassador","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Leonard Wheeler, a former NFL player who underwent TULSA procedure for prostate cancer, joins Profound as Global Ambassador to promote TULSA-PRO.","Wheeler's mission includes driving awareness, adoption, and advocacy for TULSA-PRO through digital media, social media, and podcasting.","Profound's 2025 deliverables focus on physician, patient, and private payer awareness and access for the incision-free, AI-powered ablation therapy.","The TULSA procedure uses real-time MR guidance and AI-enhanced planning to treat prostate cancer while preserving urinary continence and sexual function."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":345207533.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157013,"accession_number":"0001171843-25-003194","cik":1628808,"company_name":"Profound Medical Corp.","ticker":"PROF","form_type":"8-K","filed_at":"2025-05-14T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Shareholders elect all six directors, approve auditor and share option plan","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All six director nominees elected with 92.4%-97.0% votes for; Arun Menawat received 94.5%.","PricewaterhouseCoopers LLP appointed as auditor with 99.489% votes for (20,467,738 for).","Ordinary resolution approving unallocated options under share option plan passed with 68.271% for (8,050,144 for)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":345207533.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157012,"accession_number":"0001171843-25-002987","cik":1628808,"company_name":"Profound Medical Corp.","ticker":"PROF","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Profound Medical Q1 2025 revenue $2.6M (+82% YoY); net loss $10.7M vs $6.6M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $2.6M, up 82% from $1.4M in Q1 2024; gross margin 71% vs 60%.","Net loss $10.7M ($0.36/share) vs $6.6M ($0.27/share) a year ago.","Operating expenses $13.0M, up from $8.7M on commercial expansion and R&D.","Cash $46.4M at March 31; 30,053,142 shares outstanding as of May 8.","Urology APC Level 7 codes effective 2025; TULSA-AI BPH module and TULSA+ planned H2 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":0.36,"consensus_revenue_estimate":null,"consensus_revenue_actual":2621000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":345207533.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157011,"accession_number":"0001171843-25-002572","cik":1628808,"company_name":"Profound Medical Corp.","ticker":"PROF","form_type":"8-K","filed_at":"2025-04-29T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"CAPTAIN trial: TULSA shows zero blood loss, shorter stay vs robotic prostatectomy (p<0.001)","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Median blood loss 0 mL (TULSA) vs 100 mL (RP); length of stay 0.29 vs 1.24 days (p<0.001).","Significantly lower post-operative pain (NRS) through day 6 and higher overall health (EQ-5D-5L VAS) for 30 days (p<0.05).","Fewer TULSA patients reported extreme problems in mobility (0% vs 12%), self-care (3% vs 17%), usual activities (17% vs 40%) in first month.","First Level 1 RCT comparing TULSA to radical prostatectomy; 201 patients randomized across 23 sites.","CEO notes data supports insurance coverage decisions; company expects further follow-up reporting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":345207533.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157010,"accession_number":"0001171843-25-002561","cik":1628808,"company_name":"Profound Medical Corp.","ticker":"PROF","form_type":"8-K","filed_at":"2025-04-29T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Profound Medical presents CAPTAIN RCT: TULSA-PRO eliminates blood loss, overnight stay; launches TULSA-AI for BPH","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CAPTAIN RCT peri-operative data: median blood loss 0 vs 100 mL and length of stay 0.29 vs 1.24 days for TULSA vs robotic prostatectomy (p<0.001).","Patients reported significantly less pain and better overall health (EQ-5D-5L VAS) in first month after TULSA vs robotic prostatectomy (p<0.05).","Real-world CARE registry (n=223): PSA decreased 90% at 1 year; 94% pad-free continence; 77% preserved erectile function; 6.3% retreatment rate.","New TULSA-AI Volume Reduction module and Treatment ARC FDA cleared for BPH, expanding TULSA addressable market.","CAPTAIN is first RCT in localized prostate cancer to reach target enrollment (201 patients randomized 2:1 TULSA vs radical prostatectomy)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":345207533.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157009,"accession_number":"0001171843-25-002369","cik":1628808,"company_name":"Profound Medical Corp.","ticker":"PROF","form_type":"8-K","filed_at":"2025-04-22T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Profound Medical releases proxy circular for May 14, 2025 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Annual and special meeting scheduled for May 14, 2025; record date April 4, 2025.","Shareholders to vote on election of six directors, auditor appointment, and approval of unallocated stock options.","Neil Gagnon beneficially owns 11.2% of outstanding common shares.","CEO Arun Menawat beneficially owns 1.88% of shares and 28.2% of options."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":345207533.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175375,"accession_number":"0001171843-25-001319","cik":1628808,"company_name":"Profound Medical Corp.","ticker":"PROF","form_type":"8-K","filed_at":"2025-03-07T23:59:59+00:00","items":["1.01","2.02","2.03","4.02","9.01"],"status":"ready","headline":"Profound Medical restates Q1-Q3 2024 financials due to $472k revenue error; Q4 revenue up 108% YoY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue overstated by $472k in Q1 2024; prior 6-K filings for Q1-Q3 2024 no longer reliable.","Q4 2024 revenue $4.2M (+108% YoY); net loss $4.9M ($0.20/share) vs $8.9M ($0.42) in Q4 2023.","Full year 2024 revenue $10.7M; net loss $27.8M ($1.12/share) vs $28.3M ($1.34) in 2023.","New $10M CIBC revolving credit line matures March 2027; option to increase to $15M if trailing revenue exceeds $15M.","Mathieu Burtnyk promoted to President; Tom Tamberrino appointed CCO; CAPTAIN trial enrollment complete."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":345207533.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175374,"accession_number":"0001171843-25-000114","cik":1628808,"company_name":"Profound Medical Corp.","ticker":"PROF","form_type":"8-K","filed_at":"2025-01-08T23:59:59+00:00","items":["2.02","8.01"],"status":"ready","headline":"Profound Medical Q4 revenue up ~105-110% YoY; switches to US GAAP","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary Q4 2024 revenue $4.1-4.2M, YoY growth 105-110%, sequential growth 45-48%.","Preliminary FY2024 revenue $11.1-11.2M vs $7.2M in FY2023.","As of Jan 1, 2025, transitioning from IFRS to US GAAP; will file US domestic forms (10-K, 10-Q, 8-K).","TULSA procedure now reimbursed at Urology APC Level 7 across multiple treatment settings.","Company to present at JPM 2025 on Jan 16 at 11:15 a.m. PT."],"consensus_eps_estimate":null,"consensus_eps_actual":1.12,"consensus_revenue_estimate":null,"consensus_revenue_actual":10680000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":345207533.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}